Tue, May 7, 2024
Mon, May 6, 2024
Fri, May 3, 2024

Matt Miksic Maintained (TNDM) at Buy with Increased Target to $55 on, May 6th, 2024


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-increased-target-to-55-on-may-6th-2024.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matt Miksic of Barclays, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Buy with Increased Target from $39 to $55 on, May 6th, 2024.

Matt has made no other calls on TNDM in the last 4 months.



There are 7 other peers that have a rating on TNDM. Out of the 7 peers that are also analyzing TNDM, 3 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jeff Johnson of "Baird" Maintained at Hold with Increased Target to $36 on, Friday, May 3rd, 2024
  • Joanne Wuensch of "Citigroup" Maintained at Hold with Increased Target to $38 on, Wednesday, April 3rd, 2024
  • Rick Wise of "Stifel" Maintained at Hold with Increased Target to $24 on, Monday, February 5th, 2024


These are the ratings of the 4 analyists that currently disagree with Matt


  • Larry Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $50 on, Friday, May 3rd, 2024
  • Mathew Blackman of "Stifel" Maintained at Strong Buy with Increased Target to $45 on, Friday, May 3rd, 2024
  • Matt O'Brien of "Piper Sandler" Reiterated at Buy with Increased Target to $50 on, Friday, May 3rd, 2024
  • Mike Kratky of "Leerink Partners" Upgraded from Hold to Buy and Increased Target to $45 on, Thursday, April 25th, 2024

Publication Contributing Sources